Binimetinib

Last Updated: 11/08/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 466 publications

Precision Thyroid Oncology Using Genetic-Based Therapies: A Narrative Review.

Precision Thyroid Oncology Using Genetic-Based Therapies: A Narrative Review.

Journal: Thyroid : official journal of the American Thyroid Association

Published: October 20, 2026

Combined talimogene laherparepvec and binimetinib in NRAS-mutated melanoma induces anti-tumor immunity.

Combined talimogene laherparepvec and binimetinib in NRAS-mutated melanoma induces anti-tumor immunity.

Journal: The Journal of clinical investigation

Published: September 29, 2026

Correction: Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trial.

Correction: Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trial.

Journal: British journal of cancer

Published: September 25, 2026

Three Cases of Encorafenib Treatment for Recurrent BRAF-Mutated Colorectal Cancer

Three Cases of Encorafenib Treatment for Recurrent BRAF-Mutated Colorectal Cancer

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: September 11, 2026

Giant scalp melanoma in an immunosuppressed patient.

Giant scalp melanoma in an immunosuppressed patient.

Journal: JAAD case reports

Published: August 16, 2026

Efficacy and safety of MEK inhibitors for NF1-associated symptomatic, inoperable plexiform neurofibromas: A systematic review and meta-analysis.

Efficacy and safety of MEK inhibitors for NF1-associated symptomatic, inoperable plexiform neurofibromas: A systematic review and meta-analysis.

Journal: PloS one

Published: July 29, 2026

Encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the BECARE (GEM-2002) trial.

Encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the BECARE (GEM-2002) trial.

Journal: Neuro-oncology advances

Published: July 17, 2026

MEKing Room: On the Quest for New Sources of Therapeutic Index in RAS/MAPK-Driven Cancers.

MEKing Room: On the Quest for New Sources of Therapeutic Index in RAS/MAPK-Driven Cancers.

Journal: Cancer research

Published: July 09, 2026

Colorectal neuroendocrine neoplasm organoids reveal the potential therapeutic value of targeting BRAF mutations.

Colorectal neuroendocrine neoplasm organoids reveal the potential therapeutic value of targeting BRAF mutations.

Journal: Journal of the Endocrine Society

Published: June 17, 2026

A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAFV600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study.

A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAFV600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 17, 2026

Incidence and predictors of hemorrhage in pediatric low-grade glioma.

Incidence and predictors of hemorrhage in pediatric low-grade glioma.

Journal: Journal of neuro-oncology

Published: May 29, 2026

An integrated in silico and SPR-based workflow identifies FDA-approved drugs as previously unrecognized SIRT3 binders.

An integrated in silico and SPR-based workflow identifies FDA-approved drugs as previously unrecognized SIRT3 binders.

Journal: Bioorganic chemistry

Published: May 23, 2026

Showing 1-12 of 466

Last Updated: 11/08/2026